Q/C Technologies, Inc. also files under QCLS, MYMD, AKER; those filings are included.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 13, 2026 | Bernstein Bruce | Director | Grant(A) | 50K | — | $0 |
| Apr 13, 2026 | Silverman Joshua | Executive Chairman, Director | Grant(A) | 100K | — | $0 |
| Apr 13, 2026 | Silverman Joshua | Executive Chairman, Director | Grant(A) | 162K | — | $0 |
| Apr 13, 2026 | White Billy Joe | Director | Grant(A) | 50K | — | $0 |
| Apr 13, 2026 | Voss Chelsea Sierra | Director | Grant(A) | 50K | — | $0 |
| Apr 13, 2026 | Glass Mitchell | Chief Medical Officer, Director | Grant(A) | 50K | — | $0 |
| Apr 13, 2026 | Friscia Stephen | Director | Grant(A) | 50K | — | $0 |
| Mar 30, 2026 | Voss Chelsea Sierra | Director | Buy(P) | 2K | $3.15 | $6K |
| Jan 16, 2026 | Voss Chelsea Sierra | Director | Grant(A) | 25K | — | $0 |
| Jan 16, 2026 | Voss Chelsea Sierra | Director | Grant(A) | 213K | — | $0 |
| Jan 16, 2026 | Voss Chelsea Sierra | Director | Grant(A) | 213K | — | $0 |
| Nov 14, 2025 | Silverman Joshua | Executive Chairman, Director | Grant(A) | 91K | — | $0 |
| Nov 14, 2025 | White Billy Joe | Director | Grant(A) | 23K | — | $0 |
| Nov 14, 2025 | Glass Mitchell | Director, Chief Medical Off., Director | Grant(A) | 11K | — | $0 |
| Nov 14, 2025 | PharmaCyte Biotech, Inc. | 10% Owner | Buy(P) | 890K | — | — |
| Nov 14, 2025 | Rauch Gary M | Insider | Grant(A) | 11K | — | $0 |
| Nov 14, 2025 | Bernstein Bruce | Director | Grant(A) | 25K | — | $0 |
| Nov 14, 2025 | Friscia Stephen | Director | Grant(A) | 23K | — | $0 |
| Oct 3, 2025 | White Billy Joe | Director | Grant(A) | 2K | — | $0 |
| Oct 3, 2025 | Friscia Stephen | Director | Grant(A) | 2K | — | $0 |
| Oct 3, 2025 | Glass Mitchell | Director, Chief Medical Off., Director | Grant(A) | 1K | — | $0 |
| Oct 3, 2025 | Rauch Gary M | Insider | Grant(A) | 1K | — | $0 |
| Oct 3, 2025 | Silverman Joshua | Executive Chairman, Director | Grant(A) | 9K | — | $0 |
| Sep 4, 2025 | PharmaCyte Biotech, Inc. | 10% Owner | Buy(P) | 890K | — | — |
| Apr 17, 2025 | Rhodes Ian | Interim CFO | Grant(A) | 25K | — | $0 |
| Apr 17, 2025 | Rauch Gary M | Insider | Grant(A) | 75K | — | $0 |
| Apr 17, 2025 | Glass Mitchell | President, CMO, Director | Grant(A) | 125K | — | $0 |
| Aug 24, 2023 | Rivard Paul | Chief Legal Officer | Buy(P) | 150K | $1.11 | $167K |
| Aug 17, 2023 | Rivard Paul | Chief Legal Officer | Buy(P) | 25K | $1.12 | $28K |
| Jun 7, 2023 | Rivard Paul | Chief Legal Officer | Grant(A) | 150K | — | $0 |
| Jun 7, 2023 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 300K | — | $0 |
| Jun 7, 2023 | White Billy Joe | Director | Grant(A) | 150K | — | $0 |
| Jun 7, 2023 | Kaplin Adam | Chief Scientific Officer | Grant(A) | 150K | — | $0 |
| Jun 7, 2023 | Uzonwanne Jude | Director | Grant(A) | 150K | — | $0 |
| Jun 7, 2023 | Silverman Joshua | Director | Grant(A) | 200K | — | $0 |
| Jun 7, 2023 | Eagle Craig | Director | Grant(A) | 475K | — | $0 |
| Jun 7, 2023 | Schreiber Christopher C | Director | Grant(A) | 150K | — | $0 |
| Apr 4, 2023 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 750K | — | $0 |
| Dec 8, 2022 | Rivard Paul | EVP of Operations, GC | Buy(P) | 10K | $1.53 | $15K |
| Nov 26, 2021 | Silverman Joshua | Director | Buy(P) | 5K | $7.55 | $38K |
| Nov 24, 2021 | Silverman Joshua | Director | Buy(P) | 7K | $6.30 | $42K |
| Nov 24, 2021 | Silverman Joshua | Director | Buy(P) | 3K | $7.09 | $23K |
| Nov 23, 2021 | Rivard Paul | EVP of Operations, GC | Buy(P) | 15K | $6.03 | $90K |
| Oct 14, 2021 | Uzonwanne Jude | Director | Grant(A) | 150K | — | $0 |
| Oct 14, 2021 | White Billy Joe | Director | Grant(A) | 150K | — | $0 |
| Oct 14, 2021 | Schreiber Christopher C | Director | Grant(A) | 150K | — | $0 |
| Oct 14, 2021 | Kaplin Adam | Chief Scientific Officer | Grant(A) | 600K | — | $0 |
| Oct 14, 2021 | Rivard Paul | EVP of Operations, GC | Grant(A) | 200K | — | $0 |
| Oct 14, 2021 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 600K | — | $0 |
| Oct 14, 2021 | Eagle Craig | Director | Grant(A) | 150K | — | $0 |
| Oct 14, 2021 | Silverman Joshua | Director | Grant(A) | 600K | — | $0 |
| Apr 16, 2021 | White Billy Joe | Director | Option exercise(M) | 110K | — | — |
| Apr 16, 2021 | White Billy Joe | Director | Tax withholding(F) | 38K | $4.94 | $189K |
| Apr 16, 2021 | White Billy Joe | Director | Option exercise(M) | 110K | — | $0 |
| Apr 16, 2021 | Silverman Joshua | Director | Tax withholding(F) | 38K | $4.94 | $189K |
| Apr 16, 2021 | Silverman Joshua | Director | Option exercise(M) | 110K | — | — |
| Apr 16, 2021 | Silverman Joshua | Director | Option exercise(M) | 110K | — | $0 |
| Apr 16, 2021 | Schroeder Robert C | Director | Option exercise(M) | 44K | — | — |
| Apr 16, 2021 | Schroeder Robert C | Director | Tax withholding(F) | 15K | $4.94 | $73K |
| Apr 16, 2021 | Schroeder Robert C | Director | Option exercise(M) | 44K | — | $0 |
| Apr 16, 2021 | Rivard Paul | EVP of Operations, GC | Grant(A) | 77K | — | — |
| Apr 16, 2021 | Rivard Paul | EVP of Operations, GC | Grant(A) | 77K | — | — |
| Apr 16, 2021 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 96K | — | — |
| Apr 16, 2021 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 96K | — | — |
| Apr 16, 2021 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 77K | — | — |
| Apr 16, 2021 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 77K | — | — |
| Apr 16, 2021 | Chapman Christopher C JR | President, Chief Med. Officer, Director | Grant(A) | 39K | — | — |
| Apr 16, 2021 | Uzonwanne Jude | Director | Grant(A) | 116K | — | — |
| Apr 16, 2021 | Schreiber Christopher C | Director | Option exercise(M) | 132K | — | — |
| Apr 16, 2021 | Schreiber Christopher C | Director | Tax withholding(F) | 46K | $4.94 | $228K |
| Apr 16, 2021 | Schreiber Christopher C | Director | Option exercise(M) | 132K | — | $0 |
| Apr 16, 2021 | Kaplin Adam | Chief Scientific Officer | Grant(A) | 154K | — | — |
| Apr 16, 2021 | Eagle Craig | Director | Grant(A) | 482K | — | — |
| Sep 11, 2020 | White Billy Joe | Director | Grant(A) | 219K | — | $0 |
| Sep 11, 2020 | Schreiber Christopher C | Exec. Chairman and President, Director | Grant(A) | 264K | — | $0 |
| Sep 11, 2020 | Silverman Joshua | Director | Grant(A) | 219K | — | $0 |
| Sep 11, 2020 | Schroeder Robert C | Director | Grant(A) | 88K | — | $0 |
| Feb 28, 2020 | Gerber Sander | 10% Owner | Sell(S) | 638 | $2.81 | $2K |
| Feb 27, 2020 | Hudson Bay Capital Management LP | 10% Owner | Sell(S) | 15K | $2.72 | $42K |
| Feb 25, 2020 | Hudson Bay Capital Management LP | 10% Owner | Sell(S) | 13K | $2.92 | $38K |
| Jan 1, 2020 | Schreiber Christopher C | Executive Chairman, Director | Option exercise(M) | 5K | — | — |
| Jan 1, 2020 | Schreiber Christopher C | Executive Chairman, Director | Option exercise(M) | 5K | — | $0 |
| Jan 1, 2020 | Silverman Joshua | Director | Option exercise(M) | 5K | — | — |
| Jan 1, 2020 | Silverman Joshua | Director | Option exercise(M) | 5K | — | $0 |
| Jan 1, 2020 | White Billy Joe | Director | Option exercise(M) | 5K | — | — |
| Jan 1, 2020 | White Billy Joe | Director | Option exercise(M) | 5K | — | $0 |
| Dec 20, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 8K | $3.02 | $24K |
| Dec 19, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 3K | $3.08 | $8K |
| Dec 18, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 8K | $3.07 | $23K |
| Dec 17, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 3K | $3.03 | $9K |
| Dec 16, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 5K | $3.07 | $15K |
| Dec 13, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 6K | $3.02 | $18K |
| Dec 12, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 21K | $2.98 | $61K |
| Dec 11, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 26K | $3.10 | $82K |
| Dec 11, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 6K | $3.05 | $18K |
| Dec 10, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 30K | $2.97 | $89K |
| Dec 9, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 19K | $2.96 | $57K |
| Dec 9, 2019 | Hudson Bay Capital Management LP | 10% Owner | Buy(P) | 50K | $2.99 | $150K |
| Oct 2, 2019 | Yeaton Howard | CEO, CFO | Grant(A) | 4K | $0.42 | $2K |
| Aug 30, 2019 | Yeaton Howard | CEO, CFO | Grant(A) | 4K | $0.43 | $2K |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Q/C Technologies, Inc., SEC CIK 0001321834. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under TNFA and shows every filing by that issuer (also filed as QCLS, MYMD, AKER).
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-15. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for TNFA